ArticleInternational journal for parasitology. Drugs and drug resistance2018
Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48.
Article in International journal for parasitology. Drugs and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Review
- Lactic Acid Bacteria as the Green and Safe Food Preservatives: Their Mechanisms, Applications and Prospects.Foods (Basel, Switzerland) · 2026Review
- Antimicrobial peptides: evolving soldiers in the battle against drug-resistant superbugs.Molecular biology reports · 2025Review
- Bacteriocin diversity, function, discovery and application as antimicrobials.Nature reviews. Microbiology · 2024Review
- BacSp222 bacteriocin as a novel ligand for TLR2/TLR6 heterodimer.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023Article
- Antimicrobial Peptides (AMPs): Potential Therapeutic Strategy against Trypanosomiases?Biomolecules · 2023Review
- Autophagy in protists and their hosts: When, how and why?Autophagy reports · 2023Article
- Advances in the preclinical characterization of the antimicrobial peptide AS-48.Frontiers in microbiology · 2023Review
- Rationally Designed Minimal Bioactive Domains of AS-48 Bacteriocin Homologs Possess Potent Antileishmanial Properties.Microbiology spectrum · 2022Article
- Embedding Biomimetic Magnetic Nanoparticles Coupled with Peptide AS-48 into PLGA to Treat Intracellular Pathogens.Pharmaceutics · 2022Article
- Nisin Induces Cell-Cycle Arrest in Free-Living Amoebae Acanthamoeba castellanii.Acta parasitologica · 2022Article
- Different Drugs, Same End: Ultrastructural Hallmarks of Autophagy in Pathogenic Protozoa.Frontiers in microbiology · 2022Review
- The Role of Key Amino Acids in the Antimicrobial Mechanism of a Bacteriocin Model Revealed by Molecular Simulations.Journal of chemical information and modeling · 2021Article
- Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.Microorganisms · 2021Review
- Antimicrobial Activity of the Circular Bacteriocin AS-48 against Clinical Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Natural bacterial isolates as an inexhaustible source of new bacteriocins.Applied microbiology and biotechnology · 2021Review
- Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci.Antibiotics (Basel, Switzerland) · 2020Article
- Preclinical studies of toxicity and safety of the AS-48 bacteriocin.Journal of advanced research · 2019Article
- Insights into Chagas treatment based on the potential of bacteriocin AS-48.International journal for parasitology. Drugs and drug resistance · 2019Article
- Control of Propionibacterium acnes by natural antimicrobial substances: Role of the bacteriocin AS-48 and lysozyme.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The parasitic protozoan Trypanosoma brucei is the causative agent of human African trypanosomiasis (sleeping sickness) and nagana. Current drug therapies have limited efficacy, high toxicity and/or are continually hampered by the appearance of resistance. Antimicrobial peptides have recently attracted attention as potential parasiticidal compounds. Here, we explore circular bacteriocin AS-48's ability to kill clinically relevant bloodstream forms of T. brucei gambiense, T. brucei rhodesiense and T. brucei brucei. AS-48 exhibited excellent anti-trypanosomal activity in vitro (EC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.